Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis.

Autor: Hauber B; Pfizer Inc., New York, NY, USA., Hong A; Pfizer Inc., New York, NY, USA., Hunsche E; Sumitomo Pharma Switzerland GmbH, Basel, Switzerland., Maculaitis MC; Oracle Life Sciences, Austin, TX, USA., Collins SP; Medstar Georgetown University Hospital, 3800 Reservoir Rd. NW, Washington, DC, 20007, USA. Sean.P.Collins@gunet.georgetown.edu.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2024 Oct; Vol. 41 (10), pp. 3934-3950. Date of Electronic Publication: 2024 Aug 21.
DOI: 10.1007/s12325-024-02955-1
Abstrakt: Introduction: Medical androgen deprivation therapy (ADT) options have expanded for patients with advanced prostate cancer (PC). Historically, ADT was primarily available in long-acting injectable formulations. In 2020, the first oral formulation was US Food and Drug Administration-approved for adults with advanced PC. This study's aim was to assess patient preferences for attributes of medical ADT, including mode of administration, side effects, impact on sexual interest, and out-of-pocket (OOP) costs, and to segment respondents into distinct groups based on their treatment choice patterns.
Methods: A cross-sectional survey was conducted among US residents aged > 40 years with PC, employing a discrete choice experiment to assess preferences for ADT attributes. For each choice task, respondents were asked to select the hypothetical treatment profile that they preferred out of two presented. Latent class analysis (LCA) was conducted to estimate attribute-level preference weights and calculate attribute relative importance for groups of respondents with similar treatment preferences.
Results: A total of 304 respondents completed the survey (mean age 64.4 years). LCA identified four preference groups, named according to the attribute each group considered most important: Sexual interest, Cost-sensitive, Favors daily pill, and Favors injection. Most respondents in the Sexual interest group were < 65 years, while the Cost-sensitive group was mostly ≥ 65 years. Favors daily pill had the highest proportion of ADT-naïve individuals. On average, respondents in these groups preferred an oral medication. Favors injection, which had the highest proportion of ADT-experienced individuals, preferred infrequent intramuscular injections, lower chance of post-ADT testosterone recovery, and lower OOP cost.
Conclusion: Respondents differed in their preferences regarding ADT attributes, highlighting the need for patient involvement in their treatment decisions. Effective communication between healthcare providers and patients about the benefits and risks of available therapies should be encouraged to ensure that patients receive the PC treatment that best meets their needs.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: